Xiaoyan Shen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xiaoyan Shen has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Chengxiang Xia
Beijing Institute for Stem Cell and Regenerative Medicine Beijing China
1 shared publicationDehao Huang
Key Laboratory of Organ Regeneration and Reconstruction, State Key Laboratory of Stem Cell and Reproductive Biology Institute of Zoology, Chinese Academy of Sciences Beijing China
1 shared publicationFangxiao Hu
Beijing Institute for Stem Cell and Regenerative Medicine Beijing China
1 shared publicationFengzhi Feng
†Departments of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China
1 shared publication- Jianliu Wang
Peking University People’s Hospital
1 shared publication - Jie Hao
Beijing Institute for Stem Cell and Regeneration Medicine Beijing China
1 shared publication
Latest Publications
- Open Access
- 26 March 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1790210
Reversing chemoresistance in ovarian cancer: network pharmacology reveals how hydroxychloroquine/sulfasalazine duotherapy remodels tumor inflammatory–immune microenvironment
Introduction: Chemoresistance is a key contributor of ovarian cancer (OC) mortality. Clinical observations of extended survival in OC patients with rheumatic comorbidities following anti-rheumatic treatment suggest hydroxychloroquine (HCQ) and sulfasalazine (SSZ) could act as chemosensitizers. However, how the HCQ/SSZ combination counteracts platinum–taxane resistance remains unclear. Methods: A multiomics strategy was applied, integrating transcriptomics from resistant and sensitive OC models with network pharmacology, consensus clustering, machine learning, and molecular docking, which indicated potential binding to predicted targets (e.g., SSZ–tumor necrosis factor (TNF): −6.99 kcal/mol). Validation included in vitro drug sensitivity assays and clinical cytokine profiling. Results: Analysis identified 26 overlapping genes as shared targets and classified patients into chemoresistant (Subtype 1) and chemosensitive (Subtype 2) subgroups, with Subtype 1 associated with protumorigenic pathway enrichment, immunosuppressive features, and poorer prognosis. A seven-hub-gene predictive signature was established. HCQ/SSZ appeared to remodel the inflammatory–immune tumor microenvironment, primarily through cytokine and nuclear factor kappa B (NF-κB) signaling. Clinical cytokine data supported a localized immunosuppressive niche, and in vitro evidence confirmed cytotoxic effects. Patients receiving long-term HCQ/SSZ therapy generally showed improved clinical outcomes. Conclusion: This study suggests that HCQ/SSZ may reverse chemoresistance by reprogramming the inflammatory–immune microenvironment, offering a molecular rationale for further investigation into their repurposing as chemosensitizers and maintenance therapies in OC.
- 26 March 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1790210
Open AccessReversing chemoresistance in ovarian cancer: network pharmacology reveals how hydroxychloroquine/sulfasalazine duotherapy remodels tumor inflammatory–immune microenvironment
Introduction: Chemoresistance is a key contributor of ovarian cancer (OC) mortality. Clinical observations of extended survival in OC patients with rheumatic comorbidities following anti-rheumatic treatment suggest hydroxychloroquine (HCQ) and sulfasalazine (SSZ) could act as chemosensitizers. However, how the HCQ/SSZ combination counteracts platinum–taxane resistance remains unclear. Methods: A multiomics strategy was applied, integrating transcriptomics from resistant and sensitive OC models with network pharmacology, consensus clustering, machine learning, and molecular docking, which indicated potential binding to predicted targets (e.g., SSZ–tumor necrosis factor (TNF): −6.99 kcal/mol). Validation included in vitro drug sensitivity assays and clinical cytokine profiling. Results: Analysis identified 26 overlapping genes as shared targets and classified patients into chemoresistant (Subtype 1) and chemosensitive (Subtype 2) subgroups, with Subtype 1 associated with protumorigenic pathway enrichment, immunosuppressive features, and poorer prognosis. A seven-hub-gene predictive signature was established. HCQ/SSZ appeared to remodel the inflammatory–immune tumor microenvironment, primarily through cytokine and nuclear factor kappa B (NF-κB) signaling. Clinical cytokine data supported a localized immunosuppressive niche, and in vitro evidence confirmed cytotoxic effects. Patients receiving long-term HCQ/SSZ therapy generally showed improved clinical outcomes. Conclusion: This study suggests that HCQ/SSZ may reverse chemoresistance by reprogramming the inflammatory–immune microenvironment, offering a molecular rationale for further investigation into their repurposing as chemosensitizers and maintenance therapies in OC.
- Open Access
- 13 August 2024
- Published by Wiley in Cell Proliferation
- Vol. 57 (12) , e13727
Mesothelin CAR‐engineered NK cells derived from human embryonic stem cells suppress the progression of human ovarian cancer in animals
CAR‐NK cell therapy does not require HLA matching and has minimal side effects. However, traditional methods of engineering CARs into human tissue‐derived NK cells exhibit heterogeneity, low transduction efficiency, and high manufacturing costs. Here, we provide a reliable approach for generating large‐scale and cryopreserved mesothelin (MSLN) CAR‐NK cells from human embryonic stem cells (hESCs) as an alternative cell source. We first constructed MSLN CAR‐expressing hESCs to reduce CAR engineering costs and subsequently differentiated these stem cells into MSLN CAR‐NK cells via an efficient organoid induction system. The MSLN CAR‐NK cells exhibit the typical expression patterns of activating receptors, inhibitory receptors, and effector molecules of NK cells. In the presence of tumour cells, the MSLN CAR‐NK cells show increased secretion of IFN‐γ and TNF‐α, as well as elevated CD107a expression level compared with induced NK cells. We cryopreserved the MSLN CAR‐NK cells in liquid nitrogen using a clinical‐grade freezing medium (CS10) for more than 6 months to mimic an off‐the‐shelf CAR‐NK cell product. The thawed MSLN CAR‐NK cells immediately recovered after 48–72‐h culture and effectively eliminated ovarian tumour cells, including human primary ovarian tumour cells from patients. The thawed MSLN CAR‐NK cells efficiently suppressed ovarian tumour development in vivo and prolonged the survival of tumour‐bearing mice. Our study provides insights into the clinical translation of hESC‐derived MSLN CAR‐NK cells as a promising off‐the‐shelf cell product.
- 13 August 2024
- Published by Wiley in Cell Proliferation
- Vol. 57 (12) , e13727
Open AccessMesothelin CAR‐engineered NK cells derived from human embryonic stem cells suppress the progression of human ovarian cancer in animals
CAR‐NK cell therapy does not require HLA matching and has minimal side effects. However, traditional methods of engineering CARs into human tissue‐derived NK cells exhibit heterogeneity, low transduction efficiency, and high manufacturing costs. Here, we provide a reliable approach for generating large‐scale and cryopreserved mesothelin (MSLN) CAR‐NK cells from human embryonic stem cells (hESCs) as an alternative cell source. We first constructed MSLN CAR‐expressing hESCs to reduce CAR engineering costs and subsequently differentiated these stem cells into MSLN CAR‐NK cells via an efficient organoid induction system. The MSLN CAR‐NK cells exhibit the typical expression patterns of activating receptors, inhibitory receptors, and effector molecules of NK cells. In the presence of tumour cells, the MSLN CAR‐NK cells show increased secretion of IFN‐γ and TNF‐α, as well as elevated CD107a expression level compared with induced NK cells. We cryopreserved the MSLN CAR‐NK cells in liquid nitrogen using a clinical‐grade freezing medium (CS10) for more than 6 months to mimic an off‐the‐shelf CAR‐NK cell product. The thawed MSLN CAR‐NK cells immediately recovered after 48–72‐h culture and effectively eliminated ovarian tumour cells, including human primary ovarian tumour cells from patients. The thawed MSLN CAR‐NK cells efficiently suppressed ovarian tumour development in vivo and prolonged the survival of tumour‐bearing mice. Our study provides insights into the clinical translation of hESC‐derived MSLN CAR‐NK cells as a promising off‐the‐shelf cell product.
- Open Access
- 17 March 2022
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 10, 772701
Identification of the Immune Signatures for Ovarian Cancer Based on the Tumor Immune Microenvironment Genes
Ovarian cancer (OV) is a deadly gynecological cancer. The tumor immune microenvironment (TIME) plays a pivotal role in OV development. However, the TIME of OV is not fully known. Therefore, we aimed to provide a comprehensive network of the TIME in OV. Gene expression data and clinical information from OV patients were obtained from the Cancer Genome Atlas Program (TCGA) database. Non-negative Matrix Factorization, NMFConsensus, and nearest template prediction algorithms were used to perform molecular clustering. The biological functions of differentially expressed genes (DEGs) were identified using Metascape, gene set enrichment analysis (GSEA), gene ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. The copy number variations (CNVs), single nucleotide polymorphisms (SNPs) and tumor mutation burden were analyzed using Gistic 2.0, R package maftools, and TCGA mutations, respectively. Estimation of STromal and Immune cells in MAlignant Tumor tissues using Expression data and CIBERSORT were utilized to elucidate the TIME. Moreover, external data from the International Cancer Genome Consortium (ICGC) and ArrayExpress databases were used to validate the signature. All 361 samples from the TCGA OV dataset were classified into Immune Class and non-Immune Class with immune signatures. By comparing the two classes, we identified 740 DEGs that accumulated in immune-related, cancer-related, inflammation-related biological functions and pathways. There were significant differences in the CNVs between the Immune and non-Immune Classes. The Immune Class was further divided into immune-activated and immune-suppressed subtypes. There was no significant difference in the top 20 genes in somatic SNPs among the three groups. In addition, the immune-activated subtype had significantly increased proportions of CD4 memory resting T cells, T cells, M1 macrophages, and M2 macrophages than the other two groups. The qRT-PCR results indicated that the mRNA expression levels of RYR2, FAT3, MDN1 and RYR1 were significantly down-regulated in OV compared with normal tissues. Moreover, the signatures of the TIME were validated using ICGC cohort and the ArrayExpress cohort. Our study clustered the OV patients into an immune-activated subtype, immune-suppressed subtype, and non-Immune Class and provided potential clues for further research on the molecular mechanisms and immunotherapy strategies of OV.
- 17 March 2022
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 10, 772701
Open AccessIdentification of the Immune Signatures for Ovarian Cancer Based on the Tumor Immune Microenvironment Genes
Ovarian cancer (OV) is a deadly gynecological cancer. The tumor immune microenvironment (TIME) plays a pivotal role in OV development. However, the TIME of OV is not fully known. Therefore, we aimed to provide a comprehensive network of the TIME in OV. Gene expression data and clinical information from OV patients were obtained from the Cancer Genome Atlas Program (TCGA) database. Non-negative Matrix Factorization, NMFConsensus, and nearest template prediction algorithms were used to perform molecular clustering. The biological functions of differentially expressed genes (DEGs) were identified using Metascape, gene set enrichment analysis (GSEA), gene ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. The copy number variations (CNVs), single nucleotide polymorphisms (SNPs) and tumor mutation burden were analyzed using Gistic 2.0, R package maftools, and TCGA mutations, respectively. Estimation of STromal and Immune cells in MAlignant Tumor tissues using Expression data and CIBERSORT were utilized to elucidate the TIME. Moreover, external data from the International Cancer Genome Consortium (ICGC) and ArrayExpress databases were used to validate the signature. All 361 samples from the TCGA OV dataset were classified into Immune Class and non-Immune Class with immune signatures. By comparing the two classes, we identified 740 DEGs that accumulated in immune-related, cancer-related, inflammation-related biological functions and pathways. There were significant differences in the CNVs between the Immune and non-Immune Classes. The Immune Class was further divided into immune-activated and immune-suppressed subtypes. There was no significant difference in the top 20 genes in somatic SNPs among the three groups. In addition, the immune-activated subtype had significantly increased proportions of CD4 memory resting T cells, T cells, M1 macrophages, and M2 macrophages than the other two groups. The qRT-PCR results indicated that the mRNA expression levels of RYR2, FAT3, MDN1 and RYR1 were significantly down-regulated in OV compared with normal tissues. Moreover, the signatures of the TIME were validated using ICGC cohort and the ArrayExpress cohort. Our study clustered the OV patients into an immune-activated subtype, immune-suppressed subtype, and non-Immune Class and provided potential clues for further research on the molecular mechanisms and immunotherapy strategies of OV.
- 1 August 2011
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 21 (6) , 1124-1130
Analysis of Clinicopathologic Prognostic Factors in 9 Patients With Epithelioid Trophoblastic Tumor
- 1 August 2011
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 21 (6) , 1124-1130
Analysis of Clinicopathologic Prognostic Factors in 9 Patients With Epithelioid Trophoblastic Tumor